Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 908 Devices Inc.MASS · Entity 5564 | Director | June 10, 2026 | June 12, 2026 |
| REPLIGEN CORPRGEN · Entity 486 | Director | March 02, 2026 | March 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
908 Devices Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 44,168 |
Reported balance
After 2026-06-10 transaction · row 1
1 source rowRow 1 · 2026-06-10 · Exercise / conversion · Acquired 14,083 · Balance 44,168 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-10 · Exercise / conversion · Disposed 14,083 · Balance 0 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. F2: The RSUs became fully vested on June 10, 2026, the day prior to the 2026 Annual Meeting of the Stockholders of 908 Devices Inc. The RSUs have no expiration date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 13,656 |
Reported balance
After 2026-06-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-11 · Grant · Acquired 13,656 · Balance 13,656 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. F3: The RSUs become fully vested on June 11, 2027 or the day prior to the 2027 Annual Meeting of the Stockholders of 908 Devices Inc., whichever occurs first, subject to the reporting person's continued service through the applicable vesting date, provided that, if the reporting person terminates their service for any reason, then a prorated number of RSUs will vest. The RSUs have no expiration date. |
| Stock Option (option to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.22 · Expires 2036-06-10 | Direct | 6,209 |
Reported balance
After 2026-06-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-11 · Grant · Acquired 6,209 · Balance 6,209 F4: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following June 11, 2026, subject to the reporting person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested.
F2: The RSUs became fully vested on June 10, 2026, the day prior to the 2026 Annual Meeting of the Stockholders of 908 Devices Inc. The RSUs have no expiration date.
F3: The RSUs become fully vested on June 11, 2027 or the day prior to the 2027 Annual Meeting of the Stockholders of 908 Devices Inc., whichever occurs first, subject to the reporting person's continued service through the applicable vesting date, provided that, if the reporting person terminates their service for any reason, then a prorated number of RSUs will vest. The RSUs have no expiration date.
F4: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following June 11, 2026, subject to the reporting person's continued service through the applicable vesting date.
REPLIGEN CORP
Report date March 02, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 89,062 |
Reported balance
After 2026-03-02 transaction · row 1
1 source rowRow 1 · 2026-03-02 · Tax withholding · Disposed 9,897 · Balance 89,062 F1: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOLIFE SOLUTIONS INC
Report date October 06, 2026 · Filed October 09, 2026
Section 16 reporting ended · disclosed 2026-10-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-10-06 transaction · row 1
1 source rowRow 1 · 2026-10-06 · Disposition to issuer · Disposed 15,046 · Balance 0 F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2018 Filed Mar 6, 2018 02:21 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 74,246 | $0.00 Strike: $33.87 | $0.00 |
DisclosureSEC source: 0001140361-18-012133 · doc1.xml · derivative · entry 3 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,246 Underlying: Common Stock · 74,246 shares Expires 2028-03-01 F3 · derivative.exercise_date: The shares vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. Read SEC document |
| March 01, 2018 Filed Mar 6, 2018 02:21 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 147,623 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-012133 · doc1.xml · nonDerivative · entry 2 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,793 F2 · shares: Mr. Hunt was awarded 147,623 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Repligen Corporation's Common Stock.The Restricted Stock Units vest in equal annual installments over a nine-year period beginning on the first anniversary of the grant date. The Restricted Stock Units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| March 01, 2018 Filed Mar 6, 2018 02:21 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 38,382 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-012133 · doc1.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,170 F1 · shares: Mr. Hunt was awarded 38,382 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Repligen Corporation's Common Stock.The Restricted Stock Units vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. The Restricted Stock Units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 20:01 UTC | REPLIGEN CORP RGEN · Entity 486 | Tax withholdingCommon Stock | 8,825 | $34.91 | $308,050.75 |
DisclosureSEC source: 0001140361-18-011550 · doc1.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,788 F1 · price: Payment of tax liability made via forfeiture of 8,825 shares of Common Stock valued at a weighted average price of $34.9066 per share on February 28, 2018. Read SEC document |
| January 22, 2018 Filed Jan 24, 2018 22:04 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 8,970 | $35.95 | $322,444.59 |
DisclosureSEC source: 0001140361-18-003088 · doc1.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,613 F1 · shares: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on November 17, 2017. F2 · price: $35.947 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.58 to $36.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 10, 2017 Filed May 11, 2017 20:57 UTC | REPLIGEN CORP RGEN · Entity 486 | Tax withholdingCommon Stock | 2,275 | $37.97 | $86,392.90 |
DisclosureSEC source: 0001140361-17-019804 · doc1.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,583 F1 · shares: Payment of tax liability made via forfeiture of 2,275 shares of Common Stock valued at a weighted average price of $37.9749 per share on May 10, 2017. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 01:56 UTC | REPLIGEN CORP RGEN · Entity 486 | Tax withholdingCommon Stock | 5,972 | $32.07 | $191,524.43 |
DisclosureSEC source: 0001140361-17-010117 · doc1.xml · nonDerivative · entry 2 Hunt Anthony · CIK 0001606030 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,858 F2 · shares: Payment of tax liability made via forfeiture of 5,972 shares of Common Stock valued at a weighted average price of $32.0704 per share on March 1, 2017. Read SEC document |
| February 23, 2017 Filed Mar 2, 2017 01:56 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 64,975 | $0.00 Strike: $32.32 | $0.00 |
DisclosureSEC source: 0001140361-17-010117 · doc1.xml · derivative · entry 3 Hunt Anthony · CIK 0001606030 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,975 Underlying: Common Stock · 64,975 shares Expires 2027-02-23 F3 · derivative.exercise_date: The shares vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. Read SEC document |
| February 23, 2017 Filed Mar 2, 2017 01:56 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 32,488 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-010117 · doc1.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,830 F1 · shares: Mr. Hunt was awarded 32,488 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The Restricted Stock Units vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. The Restricted Stock Units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| February 23, 2017 Filed Mar 22, 2017 00:22 UTC Amendment | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 64,975 | $0.00 Strike: $32.40 | $0.00 |
DisclosureSEC source: 0001140361-17-012882 · doc1.xml · derivative · entry 1 Hunt Anthony · CIK 0001606030 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,975 Underlying: Common Stock · 64,975 shares Expires 2027-02-23 F1 · derivative.exercise_date: The shares vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. Read SEC document |
| November 28, 2016 Filed Nov 29, 2016 21:58 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 5,000 | $33.12 | $165,613.00 |
DisclosureSEC source: 0001140361-16-088077 · doc1.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,342 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: $33.1226 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.84 to $33.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.